Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation

This is a comparison of pregnancy achievement between two GnRH antagonist protocols which differ in the timing of GnRH antagonist initiation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Subfertility Genital Diseases Infertility Urogenital Diseases

Age range

18 year–39 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Unit for Human Reproduction

Thessaloniki, Greece

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

< 39 years of age
BMI 18.5-29.9
<= 3 previous IVF cycles

Exclusion criteria

PCOS
Endometriosis

Treatment and study plan

Cetrorelix (Cetrotide)

Drug

flexible antagonist administration according to specified criteria

Other names: Cetrorelix, Cetrotide, Serono

Primary outcomes

Luteinizing hormone rise

Time frame: 3-14 days (duration of ovarian stimulation)

Sponsors and collaborators

Lead sponsor

Aristotle University Of Thessaloniki

Other

Registry information

Official study title

Fixed Versus Flexible GnRH Antagonist Initiation

Important dates

Study start: 2005
Primary completion: 2008
Study completion: 2008
First posted: Nov 2, 2009
Registry last updated: Nov 2, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed